The T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is a promising new target along with PD-(L)1 and CTLA-4 for cancer immunotherapy, and the blockade of TIGIT and PD-L1 were found to act synergistically on T cells and NK cells’ effector functions (Johnston et al., 2014). This evidence concerns the gene TIGIT and cancer.